Preliminary clinical trial experience of CD19 CAR T cells in combination with PD-L1 blockade in patients with R/R NHL have been encouraging with 100% ORR, and 1 CR [110]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.